TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17513689

Group type: EXPERIMENTAL
Intervention: Group 1: Blood drawn without a tourniquet, sample placed in ice (‐1 degrees C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2: Blood drawn without a tourniquet, sample left at 23 degrees C
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3: Blood drawn with a tourniquet placed 5 minutes before venipuncture, sample placed in ice (‐1 degrees C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 80
Study: 15310737

Group type: EXPERIMENTAL
Intervention: 19% dietary fat intake
Number of subjects: 11

Group type: COMPARATOR
Intervention: 30% dietary fat intake
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50% dietary fat intake
Number of subjects: 11
Study: 11455373

Group type: EXPERIMENTAL
Intervention: Preemptive ibuprofen therapy (400 mg taken orally 1 hour before separator placement and 400 mg taken orally 6 hours after the initial dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Postoperative ibuprofen therapy (400 mg taken orally 1 hour before separator placement and a lactose capsule taken orally 6 hours after the initial dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination of preemptive and postoperative ibuprofen therapy (lactose capsule taken orally 1 hour before separator placement and 400 mg ibuprofen taken 6 hours after the initial placebo)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lactose capsule (control group)
Number of subjects: 41
Study: 9926482

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 200
Study: 7509219

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 0
Study: 3053941

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tabs daily for 6 weeks)
Number of subjects: 30
Study: 31623964

Group type: EXPERIMENTAL
Intervention: Social exclusion condition (virtual ball tossing game)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Repeated social exclusion experiences
Number of subjects: 84
Study: 30234397

Group type: EXPERIMENTAL
Intervention: Home Healthcare Interactive Virtual Simulation Training System (HH‐VSTS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Paper-based training group
Number of subjects: 74
Study: 28240635

Group type: EXPERIMENTAL
Intervention: Test-bolus protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bolus-tracking protocol
Number of subjects: 60
Study: 25926145

Group type: EXPERIMENTAL
Intervention: MobileMums intervention (12-week programme with personalised SMS text messages)
Number of subjects: 36000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36000
Study: 23778346

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) applied before the second treadmill test in Group A
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) applied before the first treadmill test in Group B
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (Group C) with no RIPC applied
Number of subjects: 52
Study: 21960071

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery (OPCAB)
Number of subjects: 304

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass surgery
Number of subjects: 304
Study: 19608797

Group type: EXPERIMENTAL
Intervention: Morphine (40 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fentanyl (600 mug)
Number of subjects: 90
Study: 18236783

Group type: EXPERIMENTAL
Intervention: Buccoadhesive film containing 30 mg of ketorolac tromethamine (KT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 15219660

Group type: EXPERIMENTAL
Intervention: Metastatic breast cancer patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 17
Study: 11887473

Group type: EXPERIMENTAL
Intervention: Worse periodontal health status
Number of subjects: 0
Study: 9695137

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 1 microgram/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Co-syntropin (ACTH1-24) 0.25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7974335

Group type: EXPERIMENTAL
Intervention: Factor VIII CPS‐P (pasteurised concentrate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low dose factor VIII (immune tolerance therapy)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Another concentrate (after switching from CPS‐P)
Number of subjects: 44
Study: 2686075

Group type: EXPERIMENTAL
Intervention: Alpha 2-interferon (injected intramuscularly for 10 days)
Number of subjects: 0
Study: 10746

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Thorazine
Number of subjects: 54
Study: 30893694

Group type: EXPERIMENTAL
Intervention: DBPCFC matrix for milk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: DBPCFC matrix for raw egg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sensory test for blinding of egg and milk
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Microbiological analysis of matrices
Number of subjects: 7
Study: 30646047

Group type: EXPERIMENTAL
Intervention: Usual medical care plus chiropractic care
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual medical care alone
Number of subjects: 750
Study: 26238463

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 25358867

Group type: EXPERIMENTAL
Intervention: Long-acting injectable paliperidone palmitate (PP)
Number of subjects: 3557

Group type: COMPARATOR
Intervention: Oral paliperidone extended release (Pali ER)
Number of subjects: 3557
Study: 22065105

Group type: EXPERIMENTAL
Intervention: Transcutaneous interferential (IF) electrical stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 20598010

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 17906567

Group type: EXPERIMENTAL
Intervention: 3 x 30 microg/kg rFVIIa
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 3 x 60 microg/kg rFVIIa
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 3 x 120 microg/kg rFVIIa
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16287344

Group type: EXPERIMENTAL
Intervention: 5.0 g Cr + 18 g dextrose + 4 g of sodium and potassium phosphates (CrP)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 5.0 g Cr + 20 g dextrose (Cr)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 18 g dextrose as placebo (PL)
Number of subjects: 61
Study: 12118486

Group type: EXPERIMENTAL
Intervention: Percutaneous metallic mitral valvuloplasty using a metallic valvulotome
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Percutaneous metallic mitral valvulotomy using a metallic valvulotome
Number of subjects: 57
Study: 9893070

Group type: EXPERIMENTAL
Intervention: FIXED% method (20-25% vertebral height reduction criterion)
Number of subjects: 7238

Group type: EXPERIMENTAL
Intervention: Various morphometric approaches to defining incident deformities
Number of subjects: 7238
Study: 8626880

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine once at night
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine twice daily (morning and evening)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2252999

Group type: EXPERIMENTAL
Intervention: Lumpectomy (breast conservation)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 119
Study: 6119943

Group type: EXPERIMENTAL
Intervention: Parenteral alimentation
Number of subjects: 16
Study: 30579992

Group type: EXPERIMENTAL
Intervention: Laser ablation and three times aminolaevulinic acid-based photodynamic therapy (ALA-PDT)
Number of subjects: 100
Study: 28551698

Group type: EXPERIMENTAL
Intervention: Simulated night shift
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simulated day shift
Number of subjects: 12
Study: 26246087

Group type: EXPERIMENTAL
Intervention: Probiotic (Bacillus clausii)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 22759488

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intravenous regional anaesthesia
Number of subjects: 38
Study: 21551507

Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 19958629

Group type: EXPERIMENTAL
Intervention: rAd‐p53 injection combined with cisplatin
Number of subjects: 35
Study: 17966841

Group type: EXPERIMENTAL
Intervention: Amoxicillin-EMS Sigma Pharma 875 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amoxil BD 875 mg
Number of subjects: 20
Study: 15136603

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 10
Study: 11440291

Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID for 5 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID coadministered with digoxin (375 microg once daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Digoxin (375 microg once daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg BID
Number of subjects: 16
Study: 9505774

Group type: EXPERIMENTAL
Intervention: PEEP (10 cm H2O)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional ventilation (control)
Number of subjects: 89
Study: 8055124

Group type: EXPERIMENTAL
Intervention: $1 incentive with first mailing
Number of subjects: 8356

Group type: EXPERIMENTAL
Intervention: $1 incentive with second mailing
Number of subjects: 8356

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 8356
Study: 3671257

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study: 29351650

Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) energy balance intervention
Number of subjects: 900
Study: 26806546

Group type: EXPERIMENTAL
Intervention: ViveSoy® (500 mL per day, 15 g of protein, 50 mg of isoflavones)
Number of subjects: 147
Study: 26516121

Group type: EXPERIMENTAL
Intervention: LY2495655 (LY) 315 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: LY2495655 (LY)
Number of subjects: 201
Study: 22903446

Group type: EXPERIMENTAL
Intervention: Acupuncture with meridian acupoints and three Anmian acupoints (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture with meridian acupoints (Group A)
Number of subjects: 60
Study: 16413878

Group type: EXPERIMENTAL
Intervention: Iron (12.5 mg) and folic acid (50 microg)
Number of subjects: 25490

Group type: EXPERIMENTAL
Intervention: Zinc alone (10 mg)
Number of subjects: 25490

Group type: EXPERIMENTAL
Intervention: Iron, folic acid, and zinc
Number of subjects: 25490

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25490

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (with or without zinc)
Number of subjects: 25490
Study: 12794395

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg rPAF‐AH
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg rPAF‐AH
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 10343209

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 100
Study: 8541002

Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 mg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 1850208

Group type: EXPERIMENTAL
Intervention: Once-weekly psychotherapy, family therapy, or group therapy led by paraprofessionals
Number of subjects: 168
Study: 7140566

Group type: EXPERIMENTAL
Intervention: Cimetidine (1,000 mg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Antacids (magnesium-aluminium hydroxide, neutralization capacity 564 mmol/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily)
Number of subjects: 18
Study: 31957666

Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU intramuscular injection)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study: 31708410

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab dose increase to 150 mg Q2W
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background statin therapy
Number of subjects: 0
Study: 28844193

Group type: EXPERIMENTAL
Intervention: Dual therapy with dabigatran (110 mg twice daily)
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Dual therapy with dabigatran (150 mg twice daily)
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Triple therapy with warfarin, P2Y12 inhibitor, and aspirin
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Dual therapy with dabigatran (both doses combined)
Number of subjects: 2725
Study: 26004431

Group type: EXPERIMENTAL
Intervention: Metformin treatment (dosage not specified)
Number of subjects: 220
Study: 23360409

Group type: EXPERIMENTAL
Intervention: Barriers to cervical and breast cancer screening
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Facilitators to cervical and breast cancer screening
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Knowledge about screening needs
Number of subjects: 32
Study: 21221528

Group type: EXPERIMENTAL
Intervention: Screening for depression (SCR)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 223
Study: 19104789

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day for 14 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16953381

Group type: EXPERIMENTAL
Intervention: IM aripiprazole 9.75 mg
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: IM haloperidol 6.5 mg
Number of subjects: 448

Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 448
Study: 15216689

Group type: EXPERIMENTAL
Intervention: Coagulation (Group A) - scalpel for first half, coagulation-fulgurate for second half
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cut mode (Group B) - scalpel for first half, blend cut mode for second half
Number of subjects: 73
Study: 10902797

Group type: EXPERIMENTAL
Intervention: Leptin levels in serum (30.3 +/- 14.8 ng/mL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Leptin levels in peritoneal fluid (PF) (35.9 +/- 17.4 ng/mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group serum leptin levels (15.6 +/- 8.4 ng/mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group PF leptin levels (17.5 +/- 7.2 ng/mL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Regression equations relating leptin to body mass index
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Leptin levels in earlier stages of endometriosis
Number of subjects: 28
Study: 9017127

Group type: EXPERIMENTAL
Intervention: Fenestrated prosthesis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Small‐Carrion implants
Number of subjects: 32
Study: 8326334

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 3449560

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation (experimental group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pharmacokinetically based serum level measure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Existing measures
Number of subjects: 60
Study: 29588232

Group type: EXPERIMENTAL
Intervention: 80 mg slow-release propranolol daily for 7 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 80 mg slow-release propranolol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27590374

Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 110
Study: 25230995

Group type: EXPERIMENTAL
Intervention: Early Years Education Program (EYEP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 23785525

Group type: EXPERIMENTAL
Intervention: Standard treatment with annual mass treatment for three years (3×)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Standard treatment with stopping rule (SR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enhanced treatment with annual mass treatment for three years (3×)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enhanced treatment with stopping rule (SR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: One round of mass drug administration (MDA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Three rounds of mass drug administration (MDA)
Number of subjects: 48
Study: 21038650

Group type: EXPERIMENTAL
Intervention: Entecavir + Yidu Recipe (YDR) for 6 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Entecavir alone for 6 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Entecavir + Yidu Recipe (YDR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Entecavir alone
Number of subjects: 57
Study: 20633462

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture with chondro-protector Alflutop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 0
Study: 16898996

Group type: EXPERIMENTAL
Intervention: 20-week intervention group (received intervention for two consecutive 10-week periods)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 10-week intervention group (received intervention only during the second 10 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not receiving the intervention during the first 10 weeks)
Number of subjects: 77
Study: 12918544

Group type: EXPERIMENTAL
Intervention: Novel antiplatelet and anticoagulant strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel agents targeting haemostatic pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New compounds
Number of subjects: 0
Study: 10802077

Group type: EXPERIMENTAL
Intervention: 1 g intravenous cefazolin
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 8796665

Group type: EXPERIMENTAL
Intervention: 0.075 mmol/kg gadoterate meglumine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.100 mmol/kg gadoterate meglumine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.150 mmol/kg gadoterate meglumine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.200 mmol/kg gadoterate meglumine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All doses (0.075, 0.100, 0.150, 0.200 mmol/kg)
Number of subjects: 40
Study: 1347091

Group type: EXPERIMENTAL
Intervention: Dietary intervention (D)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diet plus cholestyramine (DC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (U, control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both interventions (D and DC)
Number of subjects: 90
Study: 6186457

Group type: COMPARATOR
Intervention: Methylphenidate (placebo, low, medium, high doses)
Number of subjects: 21
Study: 30534955

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 10
Study: 28114979

Group type: EXPERIMENTAL
Intervention: Short duration antibiotic therapy (8 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Prolonged antibiotic therapy (15 days)
Number of subjects: 34
Study: 26649908

Group type: COMPARATOR
Intervention: Epidural ropivacaine 0 mg (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 50 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 100 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 150 mg
Number of subjects: 28
Study: 24937440

Group type: EXPERIMENTAL
Intervention: Tanezumab 10mg
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Tanezumab 20mg
Number of subjects: 848
Study: 21975821

Group type: EXPERIMENTAL
Intervention: Practice-based screening using PHQ-2 followed by PHQ-9 for screen positives
Number of subjects: 10929

Group type: EXPERIMENTAL
Intervention: Baseline assessment for patients with probable major depression
Number of subjects: 10929
Study: 19066345

Group type: EXPERIMENTAL
Intervention: Conventional lactate-based peritoneal dialysis solution (D)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bicarbonate/lactate-based peritoneal dialysis solution (P)
Number of subjects: 26
Study: 17599581

Group type: EXPERIMENTAL
Intervention: Surface electromyography (sEMG) evaluation post-tonsillectomy
Number of subjects: 40
Study: 14746947

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 35
Study: 12626209

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10188748

Group type: EXPERIMENTAL
Intervention: Shoulder width stance with low load (60% 1RM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Shoulder width stance with high load (75% 1RM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Narrow stance (75% shoulder width) with low and high loads
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Wide stance (140% shoulder width) with low and high loads
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ascent phase of squat
Number of subjects: 9
Study: 7596125

Group type: EXPERIMENTAL
Intervention: SIN-1 (1.0 micrograms/kg/min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ISDN (highest dose)
Number of subjects: 23